Promoter methylation-associated loss of ID4expression is a marker of tumour recurrence in human breast cancer

BMC Cancer

Table 1 Clinicopathological parameters of 170 breast cancer specimens analysed in this study.

Variable	Categorisation	n ^aanalysable	%
Clinicopathologic parameters:
Age at diagnosis:	median 57 years (range 28–87)
	<50 years	53	31.2
	≥ 50 years	117	68.8
Tumour size^c
	pT1	62	36.5
	pT2-4	91	53.5
	pT x^b	17	10
Lymph node status^c
	pN0	74	43.5
	pN1-3	62	36.5
	pN x	34	20
Histological grade
	G1	14	8.2
	G2	79	46.5
	G3	61	35.9
	G x	16	9.4
Histological type
	invasive ductal	128	75.3
	Invasive lobular	18	10.6
	other	24	14.1
Oestrogen receptor status
	negative (IRS^d 0–2)	52	30.6
	positive (IRS 3–12)	101	59.4
	IRS x	17	10
Progesterone receptor status
	negative (IRS 0–2)	57	33.5
	positive (IRS 3–12)	96	56.5
	IRS x	17	10

^aOnly female patients with primary, unilateral, invasive breast cancer were included. ^bx status unknown. ^cAccording to TNM classification by Sobin and Wittekind [37]. ^d IRS= Immuno-reactive score according to Remmele and Stegner [38].

ISSN: 1471-2407